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Phospholipids provide an amphipathic barrier between lipid droplets and the cytoplasm of cells. In this issue
of Cell Metabolism, Krahmer and colleagues (2011) define a role for phosphatidylcholine in preventing lipid
droplet coalescence and show that the rate-limiting enzyme in phosphatidylcholine synthesis is activated
through binding to lipid droplets.Lipid droplets function as a storage depot
for neutral lipids, providing a source of
substrates for ATP generation, building
materials for membrane synthesis and
repair, and precursors of hormones and
cellular second messengers for intra-
cellular signaling pathways. The neutral
lipids, primarily triglycerides and choles-
terol esters, are packaged into the core
of the lipid droplet; a monolayer of phos-
pholipids covers the surface of the droplet
and provides an amphipathic interface
with the cytosol. Various proteins deco-
rate lipid droplets, including specific
structural proteins (perilipins), enzymes
with functions in the metabolism and traf-
ficking of lipids, and a number of proteins
of unknown function. How and where lipid
droplets are assembled and how they
expand to accommodate more lipids
when excess calories are consumed and
dietary lipids are plentiful are open ques-
tions. The report from Krahmer et al. in
this issue of Cell Metabolism sheds
considerable light on the mechanisms by
which the phospholipid content of lipid
droplets is maintained (Krahmer et al.,
2011).
The most abundant phospholipid in the
limiting monolayer of the lipid droplet, as
in other cellular membranes, is phosphati-
dylcholine (Bartz et al., 2007). In animals,
phosphatidylcholine is synthesized via
two biosynthetic pathways. The major
pathway is depicted in Figure 1. The rate-
limiting step in phosphatidylcholine bio-
synthesis is catalyzed by CCT (Li and
Vance, 2008), which is encoded by two
genes in animals and Drosophila, yielding
two isoforms, CCTa and CCTb. CCTa is
the predominant isoform in most tissuesand cycles between the nucleus and cyto-
plasm. It forms a homodimer and is acti-
vated uponbinding to nuclearmembranes
or the cytoplasmic surface of the endo-
plasmic reticulum (ER) (Taneva et al.,
2008). CCT binds tomembranes depleted
of phosphatidylcholine and enriched in
anionic phospholipids via an amphi-
pathic a-helical domain. Conformational
changes induceduponmembranebinding
activate CCT. Krahmer and colleagues
now show that CCT is recruited to the
phospholipid monolayer of lipid droplets
when fatty acids are added to cells to
promote the synthesis and storage of
triglycerides in lipid droplets (Krahmer
et al., 2011). Recruitment requires the
a-helical domain of CCT and is likely facil-
itated by depletion of phosphatidylcholine
at the surfaces of lipid droplets as they
expand to accommodate newly synthe-
sized triglyceride. When CCT binds to
enlarging lipid droplets, CCT activity on
lipid droplets increases by more than
30-fold and total cellular CCT activity in-
creases by 4-fold (Krahmer et al., 2011).
Thus, the present work identifies a major
new mechanism of CCT regulation and
novel compartment for CCT binding and
activation.
How do lipid droplets form? The
enzymes catalyzing the final steps of
neutral lipid synthesis reside in the ER
(Yen et al., 2008). Thus, the most popular
hypothetical model for lipid droplet forma-
tion posits that lipid droplets originate as
a lens of neutral lipid within themembrane
bilayer of the ER membrane (Figure 1).
This model proposes that the phospho-
lipid monolayer that coats the emerging
droplet is derived from the ER. As theCell Metabolism 1core of the lipid droplet expands, the
nascent droplet recruits specific proteins
and eventually buds from the ER to form
a distinct structure, which nonetheless
remains closely associated with ER
membranes.
When cells are exposed to fatty acids,
rapid import and esterification of fatty
acids increases triglycerides and the
formation of new lipid droplets, but may
also lead to the expansion of pre-existing
lipid droplets. How triglycerides and
phospholipids are added to preformed
lipid droplets is unclear. Although CCT
forms CDP-choline at the surfaces of lipid
droplets (Krahmer et al., 2011), the final
step of phosphatidylcholine synthesis oc-
curs on the ER. The mechanisms for the
transport of phospholipids to lipid drop-
lets remain to be determined. Possible
mechanisms include transfer through
ER contact sites with lipid droplets
or via cytosolic phospholipid transfer
proteins.
Inhibition of phosphatidylcholine bio-
synthesis affects lipid droplet mor-
phology. When CCT or CK is knocked
down in cells, phosphatidylcholine syn-
thesis is attenuated and giant lipid drop-
lets are formed (Guo et al., 2008; Krahmer
et al., 2011). Experiments with lipid emul-
sions of varying composition of phospho-
lipids and triglycerides show that phos-
phatidylcholine stabilizes small micelles
that resemble lipid droplets, preventing
coalescence of the emulsified lipids into
large amorphous pools (Krahmer et al.,
2011). Other species of phospholipids
lack this property. Thus, phosphatidyl-
choline serves a unique function in stabi-
lizing lipid droplets.4, October 5, 2011 ª2011 Elsevier Inc. 437
Figure 1. Phosphatidylcholine Synthesis and Lipid Droplet Dynamics
Dietary choline is taken up across the plasma membrane (PM) and is phosphorylated by choline kinase
(CK). Phosphocholine is converted to CDP-choline by CTP:phosphocholine cytidylyltransferase (CCT),
which binds to endoplasmic reticulum (ER) membranes and the phospholipid monolayer (colored blocks)
of lipid droplets (LD) via an amphipathic helical domain (Krahmer et al., 2011); membrane binding activates
the enzyme. CDP-choline is condensedwith diglyceride (DG) tomake phosphatidylcholine (PC) by an inte-
gral protein of the ERmembrane, CDP-choline:1,2 diacylglycerol cholinephosphotransferase (CPT). Phos-
phatidylcholine (represented by red blocks) is the most abundant phospholipid in cellular membranes and
the phospholipid monolayer of lipid droplets. Lipid droplets are thought to originate as a lens of triglyceride
(TG) within the membrane bilayer of the ER. Following expansion of the triglyceride core, lipid droplets bud
out of the ER to become independent organelles in the cytoplasm of the cell. When phosphatidylcholine is
limiting in the phospholipid monolayer coating lipid droplets (inset), adjacent lipid droplets coalesce into
larger lipid droplets (Krahmer et al., 2011). Lipid droplet-associated proteins may also promote lipid
droplet fusion; candidates include SNAP23 and Fsp27/CIDEC. (Illustration by R. Hasney.)
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PreviewsMost types of cells produce numerous
small lipid droplets; however, adipocytes
within white adipose tissue maintain
single (unilocular) lipid droplets that can
be larger than 100 mm, defining the size
of the fat cell. What is the advantage
of large, unilocular lipid droplets? The
current study shows that when phos-
phatidylcholine synthesis is limited by
knocking down CCT in Drosophila, the
enlarged lipid droplets of fat body cells
are hydrolyzed very slowly, allowing
increased survival during starvation. Ex-
tending this concept to animals, pack-
aging of fat into unilocular lipid droplets
in adipocytes likely enhances fat stor-
age and thus necessitates elaborate
control mechanisms to promote lipolysis
for release of energy substrates (Lass
et al., 2011).438 Cell Metabolism 14, October 5, 2011 ª20The study by Krahmer and colleagues
suggests that a major determinant of lipid
droplet size is the phosphatidylcholine
content of the limiting monolayer; how-
ever, since phosphatidylcholine is the
most abundant phospholipid coating
adipocyte lipid droplets, maintenance of
unilocular droplets is not a function of
deficiency of this phospholipid. Lipid
droplet-associated proteins most likely
contribute to the control of lipid droplet
size through the promotion of fusion
events. One study has suggested that
SNAP23, a protein involved in secretory
vesicle fusion, is required for lipid droplet
fusion (Bostro¨m et al., 2007); however,
the current study shows no effect of
SNAP23 depletion on lipid droplet size
(Krahmer et al., 2011). A promising can-
didate for a fusion-mediating protein is11 Elsevier Inc.CIDEC/Fsp27, a protein expressed pri-
marily in adipocytes; when the Fsp27
gene is deleted in mice, adipocytes have
smaller, multilocular lipid droplets (Nish-
ino et al., 2008; Toh et al., 2008). Mecha-
nisms controlling lipid droplet size and
fusion are poorly understood. Perhaps
Fsp27 promotes local depletion of phos-
phatidylcholine, removing the surfactant
barrier between adjacent lipid droplets
and enabling fusion.
The control of lipid droplet formation,
expansion, and metabolism has become
a lively area of investigation. Elucida-
tion of the role of phosphatidylcholine in
lipid droplet dynamics is an important
new addition to this increasingly more
complex story.REFERENCES
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